tiprankstipranks
Blurbs

Analysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), Merus (MRUS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioNTech SE (BNTXResearch Report), Merus (MRUSResearch Report) and Chimerix (CMRXResearch Report) with bullish sentiments.

BioNTech SE (BNTX)

In a report released today, Zhiqiang Shu from Berenberg Bank maintained a Buy rating on BioNTech SE, with a price target of $312.00. The company’s shares closed last Monday at $127.65, close to its 52-week low of $117.08.

According to TipRanks.com, Shu has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -29.0% and a 15.6% success rate. Shu covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Monte Rosa Therapeutics, and Sensei Biotherapeutics.

Currently, the analyst consensus on BioNTech SE is a Moderate Buy with an average price target of $211.00, implying a 66.4% upside from current levels. In a report issued on September 12, H.C. Wainwright also reiterated a Buy rating on the stock with a $272.00 price target.

See the top stocks recommended by analysts >>

Merus (MRUS)

Needham analyst Ami Fadia maintained a Buy rating on Merus today and set a price target of $45.00. The company’s shares closed last Monday at $18.64.

According to TipRanks.com, Fadia is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.1% and a 34.1% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Intra-Cellular Therapies, and Avadel Pharmaceuticals.

Merus has an analyst consensus of Strong Buy, with a price target consensus of $41.60, which is a 122.1% upside from current levels. In a report issued on September 20, SVB Securities also maintained a Buy rating on the stock.

Chimerix (CMRX)

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Chimerix, with a price target of $11.00. The company’s shares closed last Monday at $1.81, close to its 52-week low of $1.27.

According to TipRanks.com, White ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -25.6% and a 21.1% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Chimerix with a $6.00 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BNTX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles